Gilead Sciences Receives Multiple FDA Approvals and Label Expansions
Gilead Sciences has seen strong performance this year, driven by both solid financial results and significant regulatory progress. The company reported second-quarter revenue of $7.8 billion, a 10% increase from the prior year, with HIV product sales reaching $5.7 billion — up 12%. Despite a non-GAAP loss per share due to acquisition-related expenses, Gilead's core business is showing resilience and growth. Recent FDA approvals have bolstered its drug portfolio. In late August, Bixlenvo was approved as an HIV regimen that simplifies treatment for certain patients. Additionally, in June, Trodelvy received a label expansion allowing it to be used as first-line therapy for metastatic triple-negative breast cancer — potentially increasing patient eligibility and revenue potential. Gilead also secured approval for Hepcludex in May, targeting chronic hepatitis delta virus infection. This adds another treatment option to its liver disease portfolio, which saw second-quarter sales rise 10% year over year to $877 million. These developments are expected to support the company's long-term revenue and earnings growth as it transitions away from reliance on Veklury for coronavirus patients.